



Express Mail No. **EV 841 454 541 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Confirmation No.: 4596

Application No.: 10/724,273

Group Art Unit: 1648

Filed: November 24, 2003

Examiner: Parkin, Jeffrey S.

For: IDENTIFICATION AND USE OF
ANTIVIRAL COMPOUNDS THAT
INHIBIT INTERACTION OF HOST CELL
PROTEINS AND VIRAL PROTEINS
REQUIRED FOR VIRAL REPLICATION

Attorney Docket No.: 6923-119

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		<input checked="" type="checkbox"/> SMALL ENTITY		<input type="checkbox"/> OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID		PRESENT EXTRA		RATE	ADDIT. FEE	OR	ADDIT. FEE
TOTAL	21	MINUS	31	0	x 25	\$	0.00	x 50	\$.00
INDEP.	4	MINUS	7	0	x 100	\$		x 200	\$ 0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						\$	0.00		\$ 0.00
TOTAL						\$	0.00	OR	\$.00

Please charge any required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: October 1, 2007

By:

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)
Jennifer J. Chheda 46,617
Jennifer J. Chheda (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosure



10-03-07

Express Mail No. EV 841 454 541 US

10/03/07
Boy
Seg

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Confirmation No.: 4596

Application No.: 10/724,273

Group Art Unit: 1648

Filed: November 24, 2003

Examiner: Parkin, Jeffrey S.

For: IDENTIFICATION AND USE OF
ANTIVIRAL COMPOUNDS THAT
INHIBIT INTERACTION OF HOST CELL
PROTEINS AND VIRAL PROTEINS
REQUIRED FOR VIRAL REPLICATION

Attorney Docket No.: 6923-119

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed May 31, 2007 ("Office Action"), and in accordance with 37 C.F.R. § 1.111, please consider the amendments and remarks set forth below in connection with the above-identified patent application. Applicants submit concurrently herewith: (1) a Petition for Extension of Time Under 37 C.F.R. § 1.136(a) for one month from August 31, 2007 up to and including September 30, 2007 with a provision authorizing payment of the required fee (in duplicate); (2) an Amendment Fee Transmittal with a provision authorizing payment of the required claim amendment fees (in duplicate); (3) a Substitute Specification and a marked-up version of the Substitute Specification, pursuant to 37 C.F.R. §§ 1.121(a)(3) and 1.125 (b) and (c); (4) a copy of the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated May 29, 2007; (5) a paper form of a Substitute Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825; (6) a Computer Readable Form (CRF) of the Substitute Sequence Listing pursuant to 37 C.F.R. §§ 1.821-1.825; and (7) an Information Disclosure Statement Under 37 C.F.R. § 1.56 and § 1.97 (in duplicate) with an accompanying revised form PTO 1449 (List of References Cited By Applicants) and copies of References A09, B01-B03 and C66-C162.

Amendments to the Specification begin on page 3 of this paper

Amendments to the Claims begin on page 4 of this paper.

Remarks begin on page 7 of this paper.